AnGes
Osaka, Japan· Est.
Japanese biotech developing gene therapies and biologics for cardiovascular and critical care conditions.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Japanese biotech developing gene therapies and biologics for cardiovascular and critical care conditions.
CardiovascularCritical CareRare Diseases
Technology Platform
Gene therapy vectors for delivering therapeutic genes and biologic development of Tie2 receptor agonists for vascular stabilization and tissue repair.
Opportunities
Multiple clinical applications for their Tie2 receptor agonist platform across different critical care settings, and potential expansion of their gene therapy platform to additional cardiovascular indications.
Risk Factors
Clinical trial failures typical of biotech development, regulatory hurdles for gene therapy products, and competition from other companies developing vascular-targeted therapies.
Competitive Landscape
Competes with other gene therapy companies in cardiovascular space and biologic developers targeting vascular stabilization; differentiation comes from their specific Tie2 receptor agonist mechanism and focus on critical care applications.